New drug cocktail targets Hard-to-Treat breast cancer
NCT ID NCT06027268
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times
Summary
This phase II study tests a combination of four drugs (trilaciclib, pembrolizumab, gemcitabine, and carboplatin) in people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. The main goals are to see how well the treatment shrinks tumors and how safe it is. The study enrolls 36 adults with this aggressive cancer type.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
Conditions
Explore the condition pages connected to this study.